Álvaro Pascual

Álvaro Pascual

Auto-generated profile, based on publicly available information

Álvaro Pascual

Unidad de Gestión Clínica de Enfermedades Infecciosas y Microbiología, Hospital Universitario Virgen Macarena

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 1998 in The Lancet
Verified
Journal Article
Closed access
LMLuis Martínez Martínez
Luis Martínez Martínez
APAlvaro Pascual
Alvaro Pascual
GJGeorge A Jacoby
George A Jacoby

1 April 2018 in Clinical Microbiology Reviews
Verified
Journal Article
Closed access
JBJesus Rodríguez Baño
Jesus Rodríguez Baño
BGBelén Gutiérrez-Gutiérrez
Belén Gutiérrez-Gutiérrez
IMIsabel Machuca
Isabel Machuca
APAlvaro Pascual
Alvaro Pascual
SUMMARY: Therapy of invasive infections due to multidrug-resistant Enterobacteriaceae (MDR-E) is challenging, and some of the few active drugs are not available in many countries. For extended-spectrum β-lactamase and AmpC producers, carbapenems are the drugs of choice, but alternatives are needed because the rate of carbapenem resistance is rising. Potential active drugs include classic and newer β-lactam–β-lactamase inhibitor combinations, cephamycins, temocillin, aminoglycosides, tigecycline, fosfomycin, and, rarely, fluoroquinolones or trimethoprim-sulfamethoxazole. These drugs might be considered in some specific situations. AmpC producers are resistant to cephamycins, but cefepime is an option. In the case of carbapenemase-producing Enterobacteriaceae (CPE), only some “second-line” drugs, such as polymyxins, tigecycline, aminoglycosides, and fosfomycin, may be active; double carbapenems can also be considered in specific situations. Combination therapy is associated with better outcomes for high-risk patients, such as those in septic shock or with pneumonia. Ceftazidime-avibactam was recently approved and is active against KPC and OXA-48 producers; the available experience is scarce but promising, although development of resistance is a concern. New drugs active against some CPE isolates are in different stages of development, including meropenem-vaborbactam, imipenem-relebactam, plazomicin, cefiderocol, eravacycline, and aztreonam-avibactam. Overall, therapy of MDR-E infection must be individualized according to the susceptibility profile, type, and severity of infection and the features of the patient.

1 July 2017 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
BGBelén Gutiérrez-Gutiérrez
Belén Gutiérrez-Gutiérrez
ESElena Salamanca
Elena Salamanca
MCMarina de Cueto
Marina de Cueto
PHPo-Ren Hsueh
Po-Ren Hsueh
PVPierluigi Viale
Pierluigi Viale
EJE Jové
E Jové

1 September 2009 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
RBRonen Ben-Ami
Ronen Ben-Ami
JBJesus Rodríguez Baño
Jesus Rodríguez Baño
HAHande Arslan
Hande Arslan
JPJohann D. D. Pitout
Johann D. D. Pitout
CQClaudine Quentin
Claudine Quentin
YCYehuda Carmeli
Yehuda Carmeli
Background. Infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae are increasing in frequency and are associated wit

4 November 2011 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
JBJesus Rodríguez Baño
Jesus Rodríguez Baño
MNMaría Dolores Navarro
María Dolores Navarro
PRPilar Retamar
Pilar Retamar
EPEncarnación Picón
Encarnación Picón
ÁPÁlvaro Pascual
Álvaro Pascual
TGthe Extended-Spectrum Beta-Lactamases-Red Espanola de Investigacion en Patologia Infecciosa/Grupo de Estudio de Infeccion Hospitalaria Group
the Extended-Spectrum Beta-Lactamases-Red Espanola de Investigacion en Patologia Infecciosa/Grupo de Estudio de Infeccion Hospitalaria Group
(See the Editorial Commentary by Perez and Bonomo, on pages 175–7 .) Background. Extended-spectrum ß-lactamase–producing Escherichia coli (ESBL-EC) is an important cause of invasive infections. Alternatives to carbapenems—considered the drugs of choice—are needed because of the emergence of carbapenemase-producing enterobacteria. The efficacy of ß-lactam/ß-lactam inhibitors (BLBLI) in such infections is controversial. Methods. The authors performed a post hoc analysis of patients with bloodstream infections due to ESBL-EC from 6 published prospective cohorts. Mortality and length of hospital stay in patients treated with an active BLBLI (amoxicillin-clavulanic acid [AMC] and piperacillin-tazobactam [PTZ]) or carbapenem were compared in 2 cohorts: the empirical therapy cohort (ETC) and the definitive therapy cohort (DTC). Confounding was controlled by multivariate analysis; for patients in the ETC, a propensity score for receiving carbapenem was also used. Results. The ETC included 103 patients (BLBLI, 72; carbapenem, 31), and the DTC included 174 (BLBLI, 54; carbapenem, 120). Mortality rates at day 30 for those treated with BLBLI versus carbapenems were 9.7% versus 19.4% for the ETC and 9.3% versus 16.7% for the DTC, respectively (P > .2, log-rank test). After adjustment for confounders, no association was found between either empirical therapy with BLBLI (adjusted hazard ratio [HR], 1.14; 95% confidence interval [CI], .29–4.40; P = .84) or definitive therapy (adjusted HR, 0.76; 95% CI, .28–2.07; P = .5) and increased mortality. Furthermore, BLBLI therapy, with respect to carbapenem, was not found to influence length of hospital stay. Conclusions. These results suggest that AMC and PTZ are suitable alternatives to carbapenems for treating patients with bloodstream infections due to ESBL-EC if active in vitro and would be particularly useful as definitive therapy.

22 September 2008 in Archives of internal medicine (1960)
Verified
Journal Article
Open access
PDF file
JBJesus Rodríguez Baño
Jesus Rodríguez Baño
JAJuan C. Alcalá
Juan C. Alcalá
JCJosé M. Cisneros
José M. Cisneros
FGFabio Grill
Fabio Grill
AOAntonio Oliver
Antonio Oliver
APAlvaro Pascual
Alvaro Pascual
Extended-spectrumβ-lactamase (ESBL)-producing Escherichia coli has emerged worldwide as a significant group of community pathogens.1,2 This is of clinical importance because E coli is the most common cause of community-acquired urinary tract infections (UTIs), and ESBL-producing isolates are frequently resistant to many of the antimicrobial agents recommended for the treatment of such infections; this is particularly true of oral agents.3 While many studies have reported the microbiological characterization of community-acquired ESBL-producing E coli, published data that are clinically orientated are scarce; the few studies published concerning risk factors or the clinical significance of such infections involved only small samples of cases and were carried out in individual centers.4-6 As the epidemiologic features of ESBL-producing organisms may show significant local variations, multicenter studies are particularly important to obtain comprehensive knowledge of risk factors for these infections. Likewise, studies that evaluate the efficacy of the few potentially useful oral drugs available for treatment are also needed.